Andrew Drabick
Family Medicine · Raleigh, NCNPI 1235262718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novo Nordisk at 26.3% of the total. Reporting peaked in 2019 at $1,499 and has fallen 86.1% since, to $208 in 2023.
Across 161 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$612
- Amgen$261
- AstraZeneca$238
- AbbVie$222
- Takeda Pharmaceuticals U.S.A., Inc.$116
- Lilly USA, LLC$85
- plus $793 from 23 others
Across 1,206 payments — averaging $237.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$122K
- Novo Nordisk AS$118K
- Esperion Therapeutics, Inc.$47K
What the payments were for
- Food & beverage$2,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $612 |
| Amgen | 18 | $261 |
| AstraZeneca | 16 | $238 |
| AbbVie(2 entities) | 16 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $116 |
| Lilly USA, LLC | 6 | $85 |
| Boehringer Ingelheim | 5 | $81 |
| Amarin Pharma, Inc. | 6 | $78 |
| Johnson & Johnson | 6 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $64 |
| Merck | 5 | $61 |
| Abbott | 2 | $45 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Sanofi Pasteur Inc. | 2 | $40 |
| GSK | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Pfizer | 2 | $23 |
| Eisai Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Dermira, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Promius Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$2,327 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 43 | $657 |
| Levothyroxine Sodium | 51 | $504 |
| Tamsulosin Hcl | 14 | $317 |
| Esomeprazole Magnesium | 15 | $300 |
| Metoprolol Succinate | 28 | $274 |
| Pantoprazole Sodium | 21 | $260 |
| Bupropion XlBupropion Hcl | 13 | $250 |
| Losartan Potassium | 34 | $237 |
| Pravastatin Sodium | 16 | $228 |
| Gabapentin | 20 | $227 |
| Telmisartan | 11 | $222 |
| Rosuvastatin Calcium | 29 | $204 |
| Lisinopril | 18 | $161 |
| Omeprazole | 14 | $154 |
| Amlodipine Besylate | 26 | $146 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Raleigh
- William CromwellRaleigh$879K
- Scott BrundleRaleigh$25K
- Mohammad BalochRaleigh$16K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.